Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autophagy Clear all
Completed Phase 1 Interventional

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

NCT02339168
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Metformin Hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

NCT03377179
View directory record Official record
Conditions
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Interventions
ABC294640, Hydroxychloroquine Sulfate 200 MG
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 21, 2026, 7:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

NCT04214418
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Cobimetinib, Hydroxychloroquine, Atezolizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Phase 1 Interventional

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

NCT01023737
View directory record Official record
Conditions
Malignant Solid Tumour
Interventions
Hydroxychloroquine, Vorinostat
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
16 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II

NCT01649947
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, Hydroxychloroquine, Bevacizumab
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Autophagy Maintains Vascular Function Through a Novel Glycolysis-linked Pathway Regulating eNOS

NCT04200560
View directory record Official record
Conditions
Vascular Diseases
Interventions
Rhythmic Handgrip Exercise, Chronic Exercise Training
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Jul 21, 2026, 7:22 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

NCT00786682
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, hydroxychloroquine
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Hamilton, New Jersey • Montclair, New Jersey • Morristown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

mTORC1 and Autophagy in Human Brown Adipocytes

NCT04206124
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Brown Fat Harvest During Anterior Neck Surgery
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jul 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

NCT03598595
View directory record Official record
Conditions
Recurrent Osteosarcoma, Refractory Osteosarcoma
Interventions
Docetaxel, Gemcitabine, Hydroxychloroquine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Early Phase 1 Interventional

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

NCT00962845
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Jul 21, 2026, 7:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer

NCT00728845
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, hydroxychloroquine, paclitaxel
Biological · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 21, 2026, 7:22 PM EDT
Terminated Phase 2 Interventional

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

NCT05576896
View directory record Official record
Conditions
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
Interventions
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

NCT01506973
View directory record Official record
Conditions
Advanced Adenocarcinoma, Metastatic Adenocarcinoma
Interventions
Hydroxychloroquine (HCQ), Gemcitabine, Abraxane
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Phase 1Phase 2 Interventional

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

NCT01510119
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Hydroxychloroquine, RAD001
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Early Phase 1 Interventional

Autophagy Induction After Bortezomib for Myeloma

NCT01594242
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 21, 2026, 7:22 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Rejuvenation of Aged Muscle Stem Cells Through Exercise

NCT03473288
View directory record Official record
Conditions
Autophagy and Apoptosis in Human Satellite Cells
Interventions
Exercise, Sedentary
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jul 21, 2026, 7:22 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

NCT05593549
View directory record Official record
Conditions
Type 2 Diabetes, Healthy Aging
Interventions
Trehalose, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jul 21, 2026, 7:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

NCT05036226
View directory record Official record
Conditions
Prostate Cancer Recurrent, Solid Tumor, Adult
Interventions
Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 21, 2026, 7:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Ethanol Induces Skeletal Muscle Autophagy

NCT03209791
View directory record Official record
Conditions
Alcoholic Liver Disease
Interventions
Biopsies
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

NCT03037437
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib (SOR), Hydroxychloroquine (HCQ)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 100 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

NCT01023477
View directory record Official record
Conditions
Carcinoma, Intraductal, Noninfiltrating, DCIS, Ductal Carcinoma In Situ
Interventions
Chloroquine Standard Dose (500mg/week), Chloroquine Low Dose (250mg/week), Breast Biopsy
Drug · Procedure
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Jul 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes

NCT03309007
View directory record Official record
Conditions
PreDiabetes, Aging
Interventions
Metformin, Placebo Oral Tablet
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
30 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jul 21, 2026, 7:22 PM EDT
Recruiting Phase 2 Interventional

Autophagy Maintenance (AUTOMAIN)

NCT06971744
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Hydroxychloroquine, Nelfinavir, Bevacizumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 21, 2026, 7:22 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Time Course for Fasting-induced Autophagy in Humans

NCT04842864
View directory record Official record
Conditions
Fasting, Autophagy, Aging Well, Ketosis, Metabolic
Interventions
Fasting
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jul 21, 2026, 7:22 PM EDT